{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:03:49Z","timestamp":1773385429123,"version":"3.50.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>To observe the interventional effect of antidepressants on advanced cancer patients from the perspective of patient benefit and analyze patient characteristics to explore reasonable drug use.<\/jats:p>\n          <jats:p>Pharmaceutical care was administered to patients with advanced cancer. From June 2018 to June 2020, 152 advanced cancer patients underwent sertraline intervention. The Hospital Anxiety\/Depression Scale (HADS) was used to screen for the risk of anxiety and depression, and patients were divided into 4 groups: high, medium, low, and no risk. Concomitant clinical symptoms and antidepressant intervention results were recorded. HADS score change and symptom improvement were used to evaluate the antidepressant intervention effect, and effective intervention time for both indicators was recorded. The guidelines for antidepressant medication for these patients were analyzed, and depression\/anxiety assessments and treatment models in this population were discussed.<\/jats:p>\n          <jats:p>We observed that concomitant refractory clinical symptoms were the main target for the antidepressant intervention. Of those considered high risk on the basis of the HADS score (i.e., \u226515 points), 41.5% had depression, 26.3% had anxiety, and 20.4% had comorbid anxiety and depression. For the 142 patients who completed the study, the improvement rate of mood-related symptoms based on the efficacy index was 78.2%, with a median of 7 days until improvement was observed. The improvement rate based on the HADS score was 57.0%, with a median of 19 days for improvement. Improvement rate and median days until improvement under both indices were statistically significant. Comparisons by risk group showed that improvement in clinical symptoms was significantly greater in the high- and medium-risk groups than in the low-risk group, and HADS score improvement was significantly greater in the high-risk group than in the other 2 groups. Moreover, sertraline improved chemotherapy tolerance, unhealthy emotions, and clinical symptoms such as fear, dyspnea, agrypnia, fatigue, and intractable pain.<\/jats:p>\n          <jats:p>We observed a positive effect of antidepressant drug intervention on refractory clinical symptoms in patients with advanced cancer that was particularly pronounced in those with a high-to-medium risk of depression and anxiety. However, the effect was not correlated with improved HADS score. Antidepression treatment improves concomitant clinical symptoms and benefits patients.<\/jats:p>","DOI":"10.1097\/md.0000000000029771","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T12:13:16Z","timestamp":1656591196000},"page":"e29771","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Clinical observation on the benefits of antidepressant intervention in advanced cancer patients"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3202-3680","authenticated-orcid":false,"given":"Bing","family":"Pu","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, The First Hospital of Zibo, Shandong Zibo, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, The First Hospital of Zibo, Shandong Zibo, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuansheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Hospital of Zibo, Shandong Zibo, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1737-903X","authenticated-orcid":false,"given":"Bo","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Hospital of Zibo, Shandong Zibo, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"R1-20250504","first-page":"4326","article-title":"Research progess on cancer-related depression [J].","volume":"38","author":"Lv","year":"2018","journal-title":"Chinese J Gerontol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"201","DOI":"10.14735\/amko2019201","article-title":"Prevalence of anxiety and depression and their impact on the quality of life of cancer patients treated with palliative antineoplasic therapy \u2013 results of the PALINT trial.","volume":"32","author":"Svetl\u00e1kova","year":"2019","journal-title":"Klin Onkol"},{"key":"R3-20250504","first-page":"80","article-title":"Timing and risk of mood disorders requiring psychotropics in long-term survivors of adult cancers: a nationwide cohort study.","volume":"236","author":"Huang","year":"2018","journal-title":"J C Disord"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.rcp.2017.04.003","article-title":"Anxiety and depression disorders in relation to the quality of life of breast cancer patients with locally advanced or disseminated stage.","volume":"47","author":"Valderrama Rios","year":"2018","journal-title":"Rev Colomb Psiquiatr"},{"key":"R5-20250504","first-page":"2006","article-title":"Research progress of mood disorders in patients with malignant tumor [J].","volume":"27","author":"Lin","year":"2020","journal-title":"Chinese J Cancer Prev Treat"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4067\/s0034-98872018000300300","article-title":"Assessment of the Hospital Anxiety and Depression Scale for cancer patients.","volume":"146","author":"Villoria","year":"2018","journal-title":"Rev Med Chil"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"451","DOI":"10.24869\/psyd.2017.451","article-title":"Factor structure and cut-off scores of the Hospital Anxiety and Depression Scale (HADS) in a Croatian sample of adult patients suffering from advanced cancer.","volume":"29","author":"Miljanovic","year":"2017","journal-title":"Psychiatr Danub"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.genhosppsych.2014.05.005","article-title":"Prevalence, correlates and recognition of depression in Chinese inpatients with cancer [J].","volume":"36","author":"Zhao","year":"2014","journal-title":"Gen Hosp Psychiatry"},{"key":"R9-20250504","first-page":"48","article-title":"Utilization analysis of antidepressants in cancer patients from 87 hospitals in China[J].","volume":"14","author":"Lin","year":"2017","journal-title":"Chinese J Drug Appl Monit"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1176\/appi.ps.201500007","article-title":"Trends in antidepressant use among U.S. cancer survivors,1999-2012 [J].","volume":"66","author":"Xiang","year":"2015","journal-title":"Psychiatr Serv"},{"key":"R11-20250504","first-page":"387","article-title":"Analysis on the incidence group psychotherapy improves the emotional state of tumor patients[J].","volume":"25","author":"Li","year":"2017","journal-title":"China J Health Psychol"},{"key":"R12-20250504","first-page":"3509","article-title":"Progressive muscle relaxation training combined with traditional Chinese medicine music intervention to improve anxiety, depression and quality of life in cancer patients[J].","volume":"25","author":"Wang","year":"2017","journal-title":"J Mod Oncol"},{"key":"R13-20250504","first-page":"2346","article-title":"The primary clinical study of mental depression in 45 patients with malignant tumor was conducted with traditional Chinese medicine and psychological intervention[J].","volume":"29","author":"Lu","year":"2011","journal-title":"Chinese Archives Tradit Chin Med"},{"key":"R14-20250504","first-page":"2859","article-title":"Research progress of drugs for the treatment of tumor-related depression [J].","volume":"24","author":"Zhang","year":"2013","journal-title":"China Pharmacy"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10549-004-2175-1","article-title":"Effect of paroxetine hydrochloride (paxil) on fatigue and depression in breast cancer patients receiving chemotherapy.","volume":"89","author":"Roscoe","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"R16-20250504","first-page":"24","article-title":"Analysis on the incidence of anxiety and depression in cancer patients and its influencing factors[J].","volume":"3","author":"Liu","year":"2012","journal-title":"Drug Eval"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.12659\/MSM.890575","article-title":"Effects of sertraline on executive function and quality of life in patients with advanced cancer.","volume":"20","author":"Li","year":"2014","journal-title":"Med Sci Monit"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/pon.4220","article-title":"Randomized, double-blind, placebo-controlled study of methylphenidate for the treatment of depression in SSRI-treated cancer patients receiving palliative care.[J].","volume":"26","author":"Sullivan","year":"2017","journal-title":"Psychooncology"},{"key":"R19-20250504","first-page":"273","article-title":"Application of active psychological intervention in hospice care for patients with advanced tumor[J].","volume":"25","author":"Li","year":"2018","journal-title":"Chinese J Cancer Prev Treat"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029771","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:09:15Z","timestamp":1746331755000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":19,"journal-issue":{"issue":"26","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029771","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]}}}